Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors

BACKGROUND: Despite impressive response rates, most patients with advanced melanoma ultimately progress following therapy with B-Raf proto-oncogene (BRAF) inhibitors (BRAFi). Therefore, frequent radiologic assessments are necessary, and reliable serum biomarkers would be beneficial for disease monit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gassenmaier, Maximilian, Lenders, Max M., Forschner, Andrea, Leiter, Ulrike, Weide, Benjamin, Garbe, Claus, Eigentler, Thomas K., Wagner, Nikolaus B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935737/
https://www.ncbi.nlm.nih.gov/pubmed/33555543
http://dx.doi.org/10.1007/s11523-021-00792-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935737/
https://www.ncbi.nlm.nih.gov/pubmed/33555543
http://dx.doi.org/10.1007/s11523-021-00792-8

Ejemplares similares